Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 11
1994 1
2014 1
2016 1
2018 1
2019 2
2021 1
2022 3
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Hoeper MM, et al. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. N Engl J Med. 2023. PMID: 36877098 Clinical Trial.
Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies.
Jain N, Sheikh MA, Bajaj D, Townsend W, Krasuski R, Secemsky E, Chatterjee S, Moles V, Agarwal PP, Haft J, Visovatti SH, Cascino TM, Rosenfield K, Nallamothu BK, Mclaughlin VV, Aggarwal V. Jain N, et al. Among authors: moles v. JACC Cardiovasc Interv. 2023 Apr 24;16(8):976-983. doi: 10.1016/j.jcin.2023.01.361. Epub 2023 Mar 22. JACC Cardiovasc Interv. 2023. PMID: 37100561 Free article.
Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working Group.
Morland K, Gerges C, Elwing J, Visovatti SH, Weatherald J, Gillmeyer KR, Sahay S, Mathai SC, Boucly A, Williams PG, Harikrishnan S, Minty EP, Hobohm L, Jose A, Badagliacca R, Lau EMT, Jing ZC, Vanderpool RR, Fauvel C, Leonidas Alves J Jr, Strange G, Pulido T, Qian J, Li M, Mercurio V, Zelt JGE, Moles VM, Cirulis MM, Nikkho SM, Benza RL, Elliott CG. Morland K, et al. Among authors: moles vm. Pulm Circ. 2023 Dec 21;13(4):e12317. doi: 10.1002/pul2.12317. eCollection 2023 Oct. Pulm Circ. 2023. PMID: 38144948 Free PMC article.
Safety of regadenoson stress testing in patients with pulmonary hypertension.
Moles VM, Cascino T, Saleh A, Mikhova K, Lazarus JJ, Ghannam M, Yun HJ, Konerman M, Weinberg RL, Ficaro EP, Corbett JR, McLaughlin VV, Murthy VL. Moles VM, et al. J Nucl Cardiol. 2018 Jun;25(3):820-827. doi: 10.1007/s12350-016-0734-6. Epub 2016 Nov 28. J Nucl Cardiol. 2018. PMID: 27896702
Physical activity and quality of life in patients with pulmonary hypertension.
Cascino TM, McLaughlin VV, Richardson CR, Behbahani-Nejad N, Moles VM, Visovatti SH, Jackson EA. Cascino TM, et al. Among authors: moles vm. Eur Respir J. 2019 Jun 20;53(6):1900028. doi: 10.1183/13993003.00028-2019. Print 2019 Jun. Eur Respir J. 2019. PMID: 30880287 Free PMC article. No abstract available.
25 results